Doxorubicin in experimental and clinical heart failure

European Journal of Cardio-thoracic Surgery

Volumn 30, Issue 4, 2006, Pages 611-616

  Christiansen, Stefan ^a   Autschbach, Rüdiger ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cardiac surgery; Doxorubicin; End stage heart failure

Indexed keywords

DOXORUBICIN;

CANCER SURVIVAL; DRUG INDUCED DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE BIOPSY; HEART SURGERY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOGS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; MODELS, ANIMAL; NEOPLASMS; SWINE;

EID: 33748764139     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2006.06.024     Document Type: Review

References (62)

1. Henderson I.C., and Frei E. Adriamycin and the heart. N Engl J Med 300 (1979) 310-312
2. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
3. Steinherz L.J., Steinherz P.G., Tan C.T.C., Heller G., and Murphy M.L. Cardiac toxicity 4-20 years after completing anthracycline therapy. J Am Med Assoc 266 (1991) 1672-1677
4. Simpson C., Herr H., and Courville K.A. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs 8 (2004) 497-501
5. Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 28 (2001) 2-7
6. Iarussi D., Indolfi P., Casale F., Coppolino P., Tedesco M.A., and DiTullio M. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 13 (2001) 1649-1660
7. Ganz W.I., Sridhar K.S., Ganz S.S., Gonzalez R., Chakko S., and Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53 (1996) 461-470
8. Mason J.W., Bristow M.R., Billingham M.E., and Daniels J.R. Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62 (1978) 857-864
9. Lefrak E.A., Pitha J., Rosenheim S., and Gottlieb J.A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32 (1973) 302-314
10. Tallaj J.A., Franco V., Rayburn B.K., Pinderski L., Benza R.L., Pamboukian S., Foley B., and Bourge R.C. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24 (2005) 2196-2201
11. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., Deb A., Szabo E., Ungvari Z., Wolin M.S., Groves J.T., and Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107 (2003) 896-904
12. Siveski-Iliskovic N., Hill M., Chow D.A., and Singal P.K. Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91 (1995) 10-15
13. Bai P., Mabley J.G., Liaudet L., Virag L., Szabo C., and Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 11 (2004) 505-508
14. Brown P.D. Synthetic inhibitors of matrix metalloproteinases. In: Parks W.C., and Mecham R.P. (Eds). Matrix metalloproteinases (1998), Academic Press, San Diego, CA 243-261
15. Heath E.I., and Grochow L.B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59 (2000) 1043-1055
16. Christiansen S., Jahn U.R., Stypmann J., Redmann K., Scheld H.H., and Hammel D. Does a suitable animal model for research on partial left ventriculectomy exist?. Thorac Cardiovasc Surg 49 (2001) 259-267
17. van Vleet J.F., Greenwood L.A., and Ferrans V.J. Pathologic features of Adriamycin toxicosis in young pigs: nonskeletal lesions. Am J Vet Res 40 (1979) 1537-1552
18. Astra L.I., Hammond R., Tarakji K., and Stephenson L.W. Doxorubicin-induced canine CHF: advantages and disadvantages. J Card Surg 18 (2003) 301-306
19. Christiansen S., Redmann K., Scheld H.H., Jahn U.R., Stypmann J., Fobker M., Gruber A.D., and Hammel D. Adriamycin-induced cardiomyopathy in the canine-an appropriate model for research on partial left ventriculectomy?. J Heart Lung Transplant 21 (2002) 783-790
20. Christiansen S., Stypmann J., Jahn U.R., Redmann K., Fobker M., Gruber A.D., Scheld H.H., and Hammel D. Partial left ventriculectomy in modified Adriamycin-induced cardiomyopathy in the dog. J Heart Lung Transplant 22 (2003) 301-308
21. Magovern J.A., Christlieb I.Y., Badylak S.F., Lantz G.C., and Kao R.L. A Model of left ventricular dysfunction caused by intracoronary Adriamycin. Ann Thorac Surg 53 (1992) 861-863
22. Shah H.R., Vaynblat M., Ramdev G., Cunningham J.N., and Chiavarelli M. Experimental cardiomyopathy as a model of chronic heart failure. J Invest Surg 10 (1997) 387-396
23. Toyoda Y., Okada M., and Kashem M.A. A canine model of dilated cardiomyopathy induced by a repetitive intracoronary doxorubicin administration. J Thorac Cardiovasc Surg 115 (1998) 1367-1373
24. Jaenke R.S. Delayed and progressive myocardial lesions after Adriamycin administration in the rabbit. Cancer Res 36 (1976) 2958-2966
25. Monnet E., and Orton E.C. Myocardial oxygen consumption is affected by dynamic cardiomyoplasty in dogs with Adriamycin-induced cardiomyopathy. J Card Surg 13 (1998) 475-483
26. Cheng W., Justicz A.G., Soberman M.S., Alazraki N.P., Santamore W.P., and Sink J.D. Effects of dynamic cardiomyoplasty on indices of left ventricular systolic and diastolic function in a canine model of chronic heart failure. J Thorac Cardiovasc Surg 103 (1992) 1207-1213
27. Cheng W., Michele J.J., Spinale F.G., Sink J.D., and Santamore W.P. Effects of cardiomyoplasty on biventricular function in canine chronic heart failure. Ann Thorac Surg 55 (1993) 893-901
28. Rigatelli G., Barbiero M., Rigatelli G., Cotogni A., Riccardi R., Cobelli F., and Carraro U. Cardiocirculatory bio-assist: is it time to reconsider demand dynamic cardiomyoplasty? Review and Future Perspectives. Am Soc Artif Intern Organs J 49 (2003) 24-29
29. Christiansen S., Brose S., and Autschbach R. Surgical therapy of end-stage heart failure. Herz 28 (2003) 380-392
30. Shah H.R., Vaynblat M., Salciccioli L., Impellizzeri P., Cunningham J.N., and Chiavarelli M. Composite cardiac binding in experimental heart failure. Ann Thorac Surg 69 (2000) 429-434
31. Vaynblat M., Chiavarelli M., Shah H.S., Ramdev G., Aron M., Zisbrod Z., and Cunningham J.N. Cardiac binding in experimental heart failure. Ann Thorac Surg 64 (1997) 81-85
32. Chaudhry P.A., Mishima T., Sharov V.G., Hawkins J., Alferness C., Paone G., and Sabbah H.N. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 70 (2000) 1275-1280
33. Power J.M., Raman J., Dornom A., Farish S.J., Burrell L.M., Tonkin A.M., Buxton B., and Alferness C.A. Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Cardiovasc Res 44 (1999) 549-555
34. Konertz W.F., Shapland E., Hotz H., Dushe S., Braun J.P., Stantke K., and Kleber F.X. Passive containment and reverse remodeling by a novel textile cardiac support device. Circulation 104 Suppl. 1 (2001) I-270-I-275
35. Oz M.C., Konertz W.F., Kleber F.X., Mohr F.W., Gummert J.F., Ostermeyer J., Lass M., Raman J., Acker M.A., and Smedira N. Global surgical experience with the Acorn cardiac support device. J Thorac Cardiovasc Surg 126 (2003) 983-991
36. Raman J.S., Power J.M., Buxton B.F., Alferness C., and Hare D. Ventricular containment as an adjunctive procedure in ischemic cardiomyopathy: early results. Ann Thorac Surg 70 (2000) 1124-1126
37. Acker M.A. Clinical results with the Acorn Cardiac Restraint Device with and without mitral valve surgery. Semin Thorac Cardiovasc Surg 17 (2005) 361-363
38. Starling R.C., and Jessup M. Worldwide clinical experience with the CorCap™ cardiac support device. J Card Fail 10 (2004) S225-S233
39. Batista R.J.V., Santos J.L.V., Takeshita N., Bocchino L., Lima P.N., and Cunha M.A. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 11 (1996) 96-97
40. Lunkenheimer P.P., Redmann K., Florek J.C., Scheld H.H., Hoffmeier A., Cryer C.W., Batista R.V., Stanton J.J., Frota Filho J.D., and Anderson R.H. Surgical reduction of ventricular radius by aspirated plication of the myocardial wall: an experimental study. J Thorac Cardiovasc Surg 126 (2003) 592-596
41. Christiansen S. Partial left ventriculectomy in patients with neoplasms and severe heart failure who are not candidates for cardiac transplantation. J Thorac Cardiovasc Surg 127 (2004) 302-303
42. Ishida M., Tomita S., Nakatani T., Fukuhara S., Hamamoto M., Nagaya N., Ohtsu Y., Suga M., Yutani C., Yagihara T., Yamada K., and Kitamura S. Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy. J Heart Lung Transplant 23 (2004) 436-445
43. Suzuki K., Murtuza B., Suzuki N., Smolenski R.T., and Yacoub M.H. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 104 Suppl. (2001) I213-I217
44. Van den Bos E.J., Davis B.H., and Taylor D.A. Transplantation of skeletal myoblasts for cardiac repair. J Heart Lung Transplant 23 (2004) 1217-1227
45. Arico M.P.E., Nespoli L., Pedroni E., Bonetti F., Vigano M., and Burgio G.R. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N Engl J Med 319 (1988) 1353
46. Luthy A., Furrer M., Waser M., Maggiorini M., Pluess H.J., Real F., Weiss B., Gallino A., and Turina M. Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. J Heart Lung Transplant 11 (1992) 815-816
47. Ward K.M., Binns H., Chin C., Webber S.A., Canter C.E., and Pahl E. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 23 (2004) 1040-1045
48. Casarotto D., Bottio T., Gambino A., Testolin L., and Gerosa G. The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation. J Thorac Cardiovasc Surg 125 (2003) 417-418
49. Fricker F.J., Addonizio L., Bernstein D., Boucek M., Boucek R., Canter C., Chinnok R., Chin C., Kichuk M., Lamour J., Pietra B., Morrow R., Rotundo K., Shaddy R., Schuette E.P., Schowengerdt K.O., Sondheimer H., and Webber S. Heart transplantation in children: indications. Report of the Ad Hoc Subcommittee of the Pediatric Committee of the American Society of Transplantation (AST). Pediatr Transplant 3 (1999) 333-342
50. Swartz M.F., Fink G.W., and Carhart R.L. Use of a biventricular assist device in the treatment of acute doxorubicin-induced cardiotoxicity. Congest Heart Fail 10 (2004) 197-199
51. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., Long J.W., Ascheim D.D., Tierney A.R., Levitan R.G., Watson J.T., and Meier P. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
52. Christiansen S., Jahn U.R., Meyer J., Scheld H.H., Van Aken H., Kehrel B.E., and Hammel D. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II. Ann Thorac Surg 69 (2000) 774-777
53. Christiansen S., Van Aken H., Breithardt G., Scheld H.H., and Hammel D. Successful cardiac transplantation after four cases of DeBakey LVAD failure. J Heart Lung Transplant 21 (2002) 706-709
54. Oz M.C., Gelijns A.C., Miller L., Wang C., Nickens P., Arons R., Aaronson K., Richenbacher W., van Meter C., Nelson K., Weinberg A., Watson J., Rose E.A., and Moskowitz A.J. Left ventricular assist devices as permanent heart failure therapy. Ann Surg 238 (2003) 577-585
55. Park S.J., Tector A., Piccioni W., Raines E., Gelijns A., Moskowitz A., Rose E., Holman W., Furukawa S., Frazier O.H., and Dembitsky W. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 129 (2005) 9-17
56. Stevenson L.W., Miller L.W., Desvigne-Nickens P., Ascheim D.D., Parides M.K., Renlund D.G., Oren R.M., Krueger S.K., Costanzo M.R., Wann L.S., Levitan R.G., and Mancini D. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy. Circulation 110 (2004) 975-981
57. Legha S.S., Benjamin R.S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S.L., Blumenschein G.R., and Freireich E.J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 (1982) 133-139
58. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., and Muggio F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
59. Shapira J., Gotfried M., Lishner M., and Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-h infusion regimen. A prospective randomized evaluation. Cancer 65 (1990) 870-873
60. Seifert C.F., Nesser M.E., and Thompson D.F. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28 (1994) 1063-1072
61. Speyer J.L., Green M.D., Sanger J., Zeleniuch-Jacquotte A., Kramer E., Rey M., Wernz J.C., Blum R.H., Hochester H., and Meyers M. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17 (1990) 161-163
62. Shaddy R.E., Olsen S.L., Bristow M.R., Taylor D.O., Bullock E.A., Tani L.Y., and Renlund D.G. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129 (1995) 197-199